Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring <b><i>EGFR</i></b> Mutations-Reference-Cited by-同舟云学术

Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

Published:2018 Issue:2 Volume:95 Page:109-115
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Nishinarita Noriko,Igawa Satoshi,Kasajima Masashi,Kusuhara Seiichiro,Harada Shinya,Okuma Yuriko,Sugita Keisuke,Ozawa Takahiro,Fukui Tomoya,Mitsufuji Hisashi,Yokoba Masanori,Katagiri Masato,Kubota Masaru,Sasaki Jiichiro,Naoki Katsuhiko

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference30 articles.

1. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al: Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006; 24: 2245–2251.

2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139.

3. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500.

4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al: EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306–13311.

5. Malik PS, Jain D, Kumar L: Epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncology 2016; 39: 605–614.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors;Respiratory Medicine and Research;2023-11

2. The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors;Oncology;2023

3. Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer;Investigational New Drugs;2020-05-15

4. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors;Investigational New Drugs;2020-03-10

5. Applications of CRISPR/Cas9 Technology in the Treatment of Lung Cancer;Trends in Molecular Medicine;2019-11